Breast cancer · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CP-EC and Pembrolizumab Variant #01 | TNBC | R 86 676 | 21d | — | — | — | — | — |
CP-AC and Pembrolizumab Variant #01 | TNBC | R 85 395 | 21d | — | — | — | — | — |
nP-ddAC and Atezolizumab Variant #01 | TNBC | R 60 687 | 14d | — | — | — | — | 1 |
nP-ddAC Variant #01 | TNBC | R 38 809 | 14d | — | — | — | — | 1 |
CP-EC Variant #01 | TNBC | R 4 689 | 21d | — | — | — | — | — |
CP-AC Variant #01 | TNBC | R 3 408 | 21d | — | — | — | — | — |
6 of 6 regimens shown